Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of Vent-02, a Novel CNS-Penetrant NLRP3 Inhibitor for the Treatment of Parkinson’s Disease
Objective: The objectives of this first-in-human study were to assess the safety, tolerability, pharmacokinetics (PK), food-effect and pharmacodynamics of VENT-02 in healthy volunteers Background: Vent-02…Early Impairment in the Immunomodulatory Function of Mesenchymal Stromal Cells Contributes to Heightened Peripheral and Neuroinflammation in Parkinson’s Disease Insights From In Vivo Chronic PD Rat Model and In Vitro PD iPSC Model
Objective: To assess the timeline dependent changes in endogenous Bone-Marrow-Mesenchymal-Stromal-Cells (BMMSC) in in-vivo chronic PD model and validating these cellular modifications in human iPSC derived…GT-02287 in Parkinson’s Disease: Interim Data from a Phase 1b Study
Objective: To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the brain-penetrant glucocerebrosidase (GCase) modulator GT-02287 in people with Parkinson’s disease with and without a…Modeling Inflammation in GBA-Associated Parkinson’s Disease: Insights into Disease Mechanisms
Objective: This investigation centers on the role of inflammation in GBA-associated Parkinson’s disease (PD), a neurodegenerative disorder characterized by the progressive degeneration of dopaminergic neurons,…A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the NLRP3 Inhibitor Vent-02 in Patients with Mild to Moderate Parkinson’s Disease
Objective: To describe the innovative Phase 2 study design aimed to investigate vent-02 in the treatment of PD. Background: NLRP3 hyperactivation plays a critical role…α-Synuclein Triggers Neuroinflammatory Damage through the suppression of MEF2C
Objective: To explore the effects of microglial myocyte enhancer factor 2C (MEF2C) in neuroinflammation induced by α-synuclein. Background: The abnormal aggregation of α-synuclein (α-syn) is a critical…Quercetin Reduces mtDNA Release in PRKN-Deficient and Oxidatively Stressed SH-SY5Y Cells
Objective: This study investigates the role of Parkin deficiency in mitochondrial dysfunction and its contribution to mitochondrial DNA (mtDNA) release in Parkinson’s disease (PD). We…Complement C4 Exacerbates Inflammation and Neuronal Damage in Vivo
Objective: To investigate the specific effects of the core complement component C4 on α-synuclein aggregation and neuroinflammation during the pathogenesis of PD. Background: Synucleinopathies are…Novel C-KIT/C-Abl Inhibitor BK40196 Alleviates Neurodegenerative Pathology And Improves Behavioral Performance In A53T Mice
Objective: Here we synthesized a novel c-KIT/c-Abl inhibitor BK40196 and investigated its effects on alpha-synuclein, neuro-inflammation , dopamine and behavior in A53T mice. Background: Inhibition…Lewy Pathology correlates with neuroinflammation in the hippocampus of Synucleinopathy patients in a subregion specific manner
Objective: The objective of this study is to examine the sub-regional differences in neuroinflammation (NI) in response to Lewy pathology (LP) within the hippocampus of…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 25
- Next Page »